Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice.
D000281:Administration, Intranasal; D019264:Adoptive Transfer; D000485:Allergens / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology; D000818:Animals; D052179:Antigens, Plant; D029662:Betula / Q000235:genetics / Q000276:immunology; D016207:Cytokines / Q000096:biosynthesis; D003888:Desensitization, Immunologic; D005260:Female; D006969:Hypersensitivity, Immediate / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*; D007108:Immune Tolerance; D018928:Immunity, Mucosal; D007073:Immunoglobulin E / Q000096:biosynthesis; D007074:Immunoglobulin G / Q000096:biosynthesis; D066298:In Vitro Techniques; D008168:Lung / Q000276:immunology / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D010940:Plant Proteins / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology; D011058:Pollen / Q000235:genetics / Q000276:immunology*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D016212:Transforming Growth Factor beta / Q000235:genetics